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Abstract 
Hyaluronic acid, or HA, is a rigid and linear biopolymer belonging to the class of the glycosaminoglycans, and 
composed of repeating units of the monosaccharides glucuronic acid and N-acetylglucosamine. HA has multiple 
important functions in the human body, due to its properties such as bio-compatibility, lubricity and hydrophilic-
ity, it is widely applied in the biomedical, food, health and cosmetic fields. The growing interest in this molecule has 
motivated the discovery of new ways of obtaining it. Traditionally, HA has been extracted from rooster comb-like 
animal tissues. However, due to legislation laws HA is now being produced by bacterial fermentation using Strepto-
coccus zooepidemicus, a natural producer of HA, despite it being a pathogenic microorganism. With the expansion of 
new genetic engineering technologies, the use of organisms that are non-natural producers of HA has also made it 
possible to obtain such a polymer. Most of the published reviews have focused on HA formulation and its effects on 
different body tissues, whereas very few of them describe the microbial basis of HA production. Therefore, for the first 
time this review has compiled the molecular and genetic bases for natural HA production in microorganisms together 
with the main strategies employed for heterologous production of HA.
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Background
Hyaluronic acid, also called hyaluronan or hyaluronate 
(HA), is considered an important glycosaminoglycans 
due to its varied physiological functions. This polymer is 
composed of disaccharide repetitions of glucuronic acid 
(UDP-GlcUA) and N-acetylglucosamine (UDP-GlcNAc), 
linked by β1 →  3 and β1 →  4 glycosidic bonds (Fig. 1) 
[1, 2]. In contrast to other glycosaminoglucans, HA is the 
only non-sulphated polymer, which allows the molecule 
to be rigid and straight [1]. It is produced in the plasma 
membrane of all mammalian cells, amphibians and bac-
teria [3] by integral membrane enzymes called hyaluronic 
acid synthases (HAS), which have several isoforms 
according to its producing organism.
In humans, HA is present in all organs and especially 
abundant in connective tissue [4]. HA reaches higher 
concentrations in the cartilage tissue in the vitreous 
humor [5], the synovial fluid of the joints [6] and in the 
umbilical cord [7] and is responsible for the mainte-
nance of tissue homeostasis [8]. This polymer is directly 
involved in processes such as embryogenesis [9], inflam-
mation [10], metastasis or tumor progression phenom-
enon [11], angiogenesis [12] and the healing process [13]. 
Another common feature of HA in eukaryotic organ-
isms is that it confers a smooth aspect to the skin. It has 
been reported that with aging, HA production decreases, 
which results in the dehydration and loss of elasticity of 
the skin, contributing to the appearance of wrinkles [14].
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The main characteristics of HA that makes it a very 
attractive molecule are: (1) high hygroscopicity; (2) vis-
coelastic nature; (3) high biocompatibility; (4) non-
immunogenicity and (5) it does not generate toxic 
products when degraded. The use of HA has seen results 
in ophthalmic cosmetics [15], in surgery [16], as a drug 
delivery system [17], in rheumatology [18], in otolaryn-
gology [19] and in urology [20]. The many applications 
of hyaluronic acid are illustrated in Fig.  2. However, of 
all the previously mentioned applications, the use of 
HA is more frequent in the field of dermatology as der-
mal filler for the treatment of wrinkles. Lastly, in tissue 
engineering, HA is used as a mechanically and physically 
appropriate support for tissue that can be implanted in 
organisms without causing allergic reactions or immune 
responses [21].
Together with the increased number of applications 
of hyaluronic acid, the market share tends to grow over 
the years. Currently, this polymer is valued at USD 1000–
5000/kg depending on its purity and size [22]. According 
to a search conducted in 2014 by the intelligence com-
pany firm “Transparency Market Research”, the market-
ing value of the HA in 2012 was USD 5.32 billion and 
should reach USD 9.85 billion by 2019. Initially, its com-
mercialization was done exclusively by extraction from 
animal tissues in the early 1940s [23]. Nevertheless, the 
disadvantages of this methodology include the loss of HA 
by degradation caused by the activity of the endogenous 
hyaluronidase enzyme, harsh extraction conditions and 
high purification costs, since animal-derived HA could 
contain contaminants such as viruses [23]. Therefore, 
alternative routes for HA production have been devel-
oped. To date, commercial hyaluronic acid is mainly 
obtained by the market through microbial fermentation. 
The use of HA from microorganisms is feasible since it is 
non-immunogenic and therefore biocompatible due to its 
highly-conserved structure among different species [24].
In the early 80s, HA started to be produced using the 
bacteria Streptococci as a host cell. However, the genus 
Streptococci is known to possess several human patho-
gens, thus, the HA purification costs using this bacteria 
genus are elevated. Therefore, other microorganisms, 
natural producers or genetically engineered ones, have 
been considered for HA production. Ideally, a perfect 
microorganism for HA production should have GRAS 
status (generally regarded as safe), not secrete any toxins 
and be able to produce the biopolymer continuously so 
it can reach at least 1 megadalton (MDa). The molecu-
lar weight (MW) and the purity of HA are indicative of 
its quality: polymers that have a greater MW (>0.5 MDa) 
have greater market value. From the microbial point 
of view, producing such a polymer is also a challenge 
because of its high metabolic energy cost. For instance, 
in order to produce a dimer of HA, three ATP molecules, 
two UTP molecules, two NAD+ molecules, one molecule 
of Acetyl-CoA and one molecule of glutamine (counting 
the energy expended towards glycolysis) are necessary for 
the synthesis of the two precursors of HA (Fig. 3).
The increased interest in HA production is reflected 
by the increased number of publications and patents 
filed over the last years. A search performed in databases 
has shown that 2220 articles and patents were published 
between 2005 and 2010. This number increased about 
2.5 times in the period from 2011 to 2015. Considering 
the constant and increased interest in HA qualities, this 
review is aimed at summarizing the basis of HA produc-
tion in naturally producing organisms and in engineered 
strains for hyper production. Most published reviews 
have focused on HA formulation and its effects in differ-
ent body tissues, whereas very few of them describe the 
Fig. 1 Molecular structure of repeating disaccharide units composed of N-acetylglucosamine and glucuronic acid, which leads to the formation 
hyaluronic acid (HA). Each unit is also depicted, with the position of each carbon atom indicated by a number
Page 3 of 19de Oliveira et al. Microb Cell Fact  (2016) 15:119 
microbial basis of HA production [25–28]. Therefore, 
this review has compiled the genetic and molecular bases 
used by the microorganisms that are currently known to 
produce hyaluronic acid together with the main strate-
gies employed for heterologous production of HA.
Main text
Basis of HA synthesis: HA‑synthases
The synthesis of a HA chain in all natural producers ini-
tially emerge from the glycolytic pathway. The two pre-
cursors, UDP-GlcUA and UDP-GlcNAc are synthesized, 
respectively, from deviations of the molecules glucose-
6-phosphate and fructose 6-phosphate from glycolysis 
(Fig. 3), in a process that occurs entirely on the inner side 
the plasma membrane in the cytoplasm. Furthermore, 
from the deviation of the glycolytic pathway to the pro-
duction HA there is also the production of molecules 
used by cells as wall polysaccharide synthesis, synthesis 
of teichoic acids and peptidoglycan (Fig.  3) which cor-
responds to 20 % of dry weight of a regular cell [25]. In 
other words, the biomass formation competes with pre-
cursors to the synthesis of hyaluronic acid [29]. Once 
available in the cell, UDP-GlcUA and UDP-GlcNAc 
are used as substrates by hyaluronan synthase enzyme 
(HAS), an enzyme that have transmembrane domains 
and catalyze the union of the two sugar precursors intra-
cellularly to finally release the chain in the extracellu-
lar matrix (Fig.  3) [30]. This process is advantageous to 
the cell since it allows the synthesis of unrestricted size 
chains, and prevent the waste energy cell for a possible 
subsequent transport chains out of the cell [31].
Although the elongation of hyaluronic acid chain 
through the plasma membrane is simple, HAS enzyme is 
an multidomain enzyme with six differente binding sites: 
(1) a UDP-GlcNAc binding site and (2) a UDP-GlcUA 
binding site, both for the capture of their precursors, (3) 
a domain GlcNAc β (1–4) transferase and (4) a domain 
UDP-GlcUA β (1–3) transferase which bind the precur-
sors to each other and (5) an HA acceptor site which 
receives the newly formed chain and (6) excretes the 
molecule out of the cell [31].
A recent review detailed the main metabolic control-
ling factors of hyaluronan synthases [32]. HA is a gly-
cosaminoglycan (GAG) synthesized outside the golgi, 
unlike other GAGs, and therefore dependent of the 
pool of precursors contained in the cytoplasm. Thus, 
the hyaluronic acid production is affected when both 
sugar nucleotide precursors are in low concentrations. 
On the other hand, an increase in the amount of precur-
sors does not significantly affect the production of GAGs 
in the golgi, but affects the production of HA [32]. The 
majority of GAGs (which are sulfated) are synthesized 
in the golgi while the HA is synthesized at the plasma 
membrane, however, the affinity of the sugar nucleotides 
receptors located in the membrane of the golgi is very 
high. This feature makes the amount of sugars into the 
golgi is high all the time, unlike the amount of the cyto-
plasm [33, 34].
Fig. 2 Biomedical applications of hyaluronic acid
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The UDP-GlcNAc is also an cell wall precursor and 
used by the cell in various other functions, coming to 
have a molar concentration equivalent to the molar 
ATP concentration [35, 36]. Thus, it is not unusual to 
observe that the amount of the UDP-GlcNAc inside the 
cell drastically affects the production of HA, even more 
than UDP-GlcUA. Previous studies have suggested that 
high concentrations of ATP and/or low concentrations of 
UDP-GlcNAc force the HAS enzyme to cleave the chain 
and release the polymer into the extracellular matrix [37]. 
Moreover, the proper balance in the synthesis of UDP-
GlcNAc/UDP-GlcUA and the balance of the glycolytic 
rate and HA synthesis rate are also important factors for 
obtaining high molecular weight HA [38].
Not only the enzymes that produce directly both 
precursors affect the HA production, but also other 
enzymes, like UDP-glucose pyrophosphorylase, which 
converts glucose-1-phosphate to UDP-glucose is critical 
for the HA synthesis. The UDP-glucose is also a metab-
olite used in the reversible synthesis of glycogen, which 
can affect the energetic state of the cell to produce HA 
[39].
In metabolic terms, the demand for ATP, UTP and 
acetyl-CoA (Fig. 3) by the cell require an energy expendi-
ture that is not always available and drastically affects the 
production of HA. Furthermore, the synthesis of 1 mol of 
UDP-GlcUA produces two moles of NADH, forcing the 
cell to find ways to recycle NAD+. In other words, a high 
rate NADH: NAD+ also inhibits HA production.
HASs are divided into two categories, designated 
Class I and Class II, based on their amino acid sequence 
homology and structural topology [30, 40]. HA synthases 
belonging to Class I are present in some species of Strep-
tococcus, viruses and vertebrates. Whereas, Class II HAS 
had so far only been described in Pasteurella multocida 
[30]. The latter differs from Class I HAS in terms of pro-
tein conformation and its relationship with the coupling 
of the plasma membrane, also affecting the mechanism of 
action of HA synthesis. Class I enzymes contain multiple 
transmembrane domains, while Class II HAS is coupled 
to the plasma membrane through a single domain near 
the carboxyl terminus by an undescribed mechanism 
[30]. Another main difference between the two classes of 
enzymes is the form of HA production, the enzymes of 
Fig. 3 Biosynthetic pathway for hyaluronic acid in Streptococci. Some intermediates are also required for cell wall synthesis. Important genes are: 
hasB (coding for UDP-glucose 6-dehygrogenase); hasC (coding for glucose-1-P uridyltransferase); hasA (HA synthase)
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Class I add the two sugar precursors (UDP-GlcUA and 
UDP-GlcNAc) at the reducing end and the enzymes of 
the Class II extend the polysaccharide chain at the non-
reducing end. Table 1 summarizes the main characteris-
tics of HA synthases from Classes I and II.
The eukaryotic Class I HA synthases show homology 
to Class I HA synthases from microorganisms, indicated 
by up to five conserved transmembrane domains, with a 
DXD motif in the cytoplasmic region of the glycosyltrans-
ferase domain (PFam: PF00535) between the second and 
third transmembrane, therefore responsible for the bind-
ing of UTP-sugars to the enzyme leading to the polym-
erization of HA. The bacterial HAS demonstrates up to 
47 % similarity within 92 % of query cover; this homol-
ogy is usually attributed to a lateral gene-exchange from 
the animal host to the bacterium that may have occurred 
in the past. Figure  4 shows the phylogenetic relation-
ship between streptococcal HAS protein sequences with 
the most relevant vertebrate model organisms in which 
HAS proteins have been reported. Hyaluronic acid pro-
duced by animals and microbes are extremely different 
in molecular weight and rate of synthesis, wherein the 
speed of synthesis in microbes is ten-fold faster than the 
speed in animals [25, 41]. However, the great similarity 
between the genes involved in the production of hyalu-
ronic acid of different cells requires a theory for the exist-
ence of this sharing. The discovery that Chrlorella virus 
cells are capable of inducing the production of hyaluronic 
acid in host cells [42] and the discovery of a has gene into 
a Bacillus anthracis plasmid confirmed the theory and 
classification of the gene has as one of the 223 candi-
dates that are capable of lateral gene transfer in bacteria 
to vertebrates [26], which explains the similarity existing 
among has genes. On the other hand, the Class II—HAS 
from Pasteurella multocida (pmHAS)—is different from 
all other HA synthases, as previously discussed, which is 
likely to be an example of convergent evolution, a phe-
nomenon in which living organisms develop similar char-
acteristics from different sources, in this case, different 
enzymes with the same product: HA [43].
It is now acknowledged that eukaryotes feature three 
HAS isoforms: HAS1, HAS2, and HAS3, encoded by 
three related HAS genes on three different chromosomes 
[2, 40]. The single exception is the frog, Xenopus laevis, 
for which four HAS encoding genes can be observed. 
Additionally, X. laevis HA synthase was reported to 
synthesize HA polymers of 20  MDa in  vitro [2, 44], in 
contrast with the Streptococcal strains that generally pro-
duce smaller MW ranges of HA (around 0.8–1.5 MDa) 
and 3 MDa in animal tissues [45].
All the three isoforms of HAS in eukaryotes are owned 
to Class I and are structurally similar in relation to 
domains e regions. The three isoforms possess an N-ter-
minal region, a cytoplasmic central region and a C-ter-
minal hydrophobic region. The central region is the most 
well preserved and has a high rate of similarity between 
the three isoforms, reaching 87  %. However, for each 
reported isoform of HAS in eukaryotes, the catalytic rate 
and mode of regulation has been shown to be different 
[2, 46]. Although each of the three isoforms have a highly 
conserved amino acid sequences, each enzyme has differ-
ent kinetic properties and mechanisms of action. HAS1 
is an enzyme that has a lower activity and is responsible 
for the maintenance of constitutive levels of HA syn-
thesis having a MW between 0.2 and 2  MDa; HAS2 is 
more active compared to HAS1, and generates HA poly-
mers with MW greater than 2 MDa. In addition, HAS2 
plays an important role in damage repair suffered by the 
tissues when they are in development and expansion, 
moreover, this isoform is involved in cardiac cushion 
Table 1 Main characteristic of HA synthases from Class I and II
ND not determined
Class I Class II
Reducing Nonreducing
Organisms Streptococcus pyogenes, S. equisimilis,  
S. uberis, mammalian and avian
Amphibian species,  
algal virus
HAS of Pasteurella multocida
Size (amino acids) 417–588 972
Membrane attachment domain 6–8 membrane-associated domains C-terminal membrane anchor
HA chain growth At reducing end At nonreducing end At nonreducing end
Reaction type Hexosyl group transfer hexosyl group transfer
Metals and ions Co2+; KCl; Mg2+; Mn2+; NaCl Co2+; Mg2+; Mn2+;
KM value [mM] 0.032–1.1 0.014-0.91
Ki value [mM] 1.2–4.5 ND
pH optimum 5–9 ND
Temperature optimum (ºC) 22–60 ND
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morphogenesis. The enzyme HAS2 is also associated 
with the production of HA involved in cell migration and 
invasion, cell proliferation, and with angiogenesis during 
development. Being the more active isoform, HAS3 is 
able to produce HA chains of various sizes (0.2–2 MDa). 
The longer chains participate in the formation of the peri-
cellular glycocalyx and are responsible for interactions 
with the cell surface receptors, while the shorter chains 
participate in processes that shape the cellular activities 
through signal transduction cascades.
Aiming to characterize and compare the enzymatic 
properties of the three HAS proteins, the three responsi-
ble genes for HA synthesis in mammals have been cloned 
and expressed either in COS-1 cell strain or rat 3Y1 fibro-
blast cell strain. Kinetic studies of these enzymes have 
shown distinctions between their stability, HA elongation 
rate and apparent KM values for the UDP-GlcNAc and 
UDP-GlcUA substrates. When the study compared the 
Vmax of the three recombinant isoforms (HAS1, HAS2, 
and HAS3), the values obtained were not significantly 
different (ranging from 330.5 to 398.5 pmol/h/unit) con-
sidering the concentrations of UDP-GlcUA as saturat-
ing (1.0  mM), whereas the Km value for UDP-GlcNAc 
of HAS1 was 1.01 mM; about three- to fourfold greater 
than those of HAS2 and HAS3, respectively [47]. This 
result strengthens the suggestion that this enzyme could 
be responsible for constitutive levels of HA as discussed 
earlier.
Microorganisms that naturally produce HA
Some bacterial pathogens such as Pasteurella multocida 
and Gram-positive Streptococcus Group A and C can 
produce and secrete HA chains [48]. The particularities 
of each producing pathway from natural HA producers 
are detailed below. It is worth noting that some eukary-
otic microorganisms also have the ability to synthesize 
HA, such as the yeast Cryptococcus neoformans and the 
green algae Chlorella sp., which occurs when it is infected 
by the Paramecium bursaria chlorella virus (or Chlorovi-
rus) (PBCV-1) [49, 50].
HA synthesis from Cryptococcus neoformans is cata-
lyzed by a glycosyltransferase (CPS1  gene) [49, 50]. 
Despite C. Neoformans’ ability to synthesize HA, there 
are no reports involving C. neoformans as a large scale 
producer of this biopolymer, possibly for being an oppor-
tunistic pathogen [50, 51].
HA synthesis by microalgal Chlorella cells occurs upon 
infection with chloroviruses [48, 52]. PBCV-1-infected 
chlorella was monitored for HA synthesis, and studies 
indicated that about 80 % produce HA during infection 
[53]. In general, the production (maximum of 1  g/L, JP 
patent 2004-283096) does not reach the values typically 
achieved using Streptococcal fermentation (Table  2). 
However, recent methods were proposed to improve the 
yield of HA production in Chlorella: (1) using isolated 
chlorovirus cells that have low growth rate (CV01 and 
CVTS1) and (2) affecting the ability of cells to reproduce 
Fig. 4 Evolutionary relationship between HA synthase proteins (HAS) in an identity percentage tree using Jalview 2.9.0b2. Acessions acquired 
through the NCBI BLAST tool, aiming for better score values in organisms, Homo sapiens, Mus musculus, Xenopus laevis aligned to the Streptococcus 
pyogenis protein sequence
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by using molecules capable of inhibit DNA synthe-
sis inside the cell, and aphidicolin [52]. The use of the 
two approaches together allowed for a concentration of 
14 µg/ml, about a 2.2-fold increase over PBCV-1 infected 
chlorella, which showed a concentration of 6.3  µg/mL 
HA.
Pasteurella multocida
Pasteurella multocida, a non-motile, Gram-negative 
coccobacillus, is a pathogen that causes pneumonia in 
piglets and calves [54]. Synthesis of HA in P. multocida 
is catalyzed by a polypeptide originating from a single 
gene (pmHAS) [30, 43]. This gene encodes for a HAS 
enzyme that polymerizes the HA chain, adding the sug-
ars glucose-6-phosphate and fructose-6-phosphate to 
the non-reducing end of the growing polymer chain. This 
characteristic allows the enzyme pmHAS to elongate 
exogenous and short chains of HA to form long chains 
in vitro. However, in vivo, the chains cannot be elongated 
due to a blockage of the enzyme by the actual HA chain 
[30].
In order to investigate which gene was responsible for 
HA synthesis in this microorganism, the entire capsule 
locus of P. multocida serogroup A:1 was cloned in E. coli 
DH5α and sequenced [55]. From this study, it was shown 
that only pmHAS was functional. However, sequence 
homology has identified hyaA and hyaC as a putative 
glycosyltransferase and a UDP-glucose dehydrogenase, 
respectively [55, 56]. Despite the fact that HA is naturally 
produced by P. multocida, there are no reports employing 
this microorganism to super-produce HA, possibly due 
to the microorganism’s pathogenicity or lack of genetic 
engineering tools. Nevertheless, it is more common to 
heterologously express pmHas genes for HA production 
in other microorganisms [57–59].
Streptococcus sp.
Streptococci are non-sporulating and non-motile Gram-
positive bacteria that have the characteristic to grow 
surrounded by a large extracellular capsule [20]. Various 
wild-type strains of Streptococci are able to produce HA, 
such as Streptococcus equisimilis (an animal pathogen) 
[60], S. pyogenes (a human pathogen) [31] and S. uberis 
(a pathogen in cattle) [61]. However, among these, the 
species Streptococcus equi subsp. equi and S. equi subsp 
zooepidemicus are the commonly used (Table 2).
The bacteria Streptococcus zooepidemicus (subspecie 
of Streptococcus equi) has a operon used for HA synthe-
sis encoded by five genes: (1) HA synthase or HasA, (2) 
UDP-glucose dehydrogenase or HasB, (3) UDP-glucose 
pyrophosphorylase or HasC, (4) UDP-N-acetylglucosa-
mine pyrophosphorylase or glmU that have a activity 
of acetyltransferase and pyrophosphorylase, and a gene 
encoding for (5) phosphoglucoisomerase [62, 63]. In S. 
pyogenes, the enzymes of the biosynthetic pathway of HA 
are regulated by a polycistronic mRNA, in other words, 
a single mRNA is transcribed from more than one gene, 
that includes HasA, HasB and HasC (involved in UDP-
glucuronic acid synthesis) [64, 65] HasB is required to 
make UDP-GlcUA, one of the two substrates needed for 
HA synthesis, which is synthesized from glucose-6-phos-
phate coming of a deviation from the glycolytic route (via 
glucose-1-phosphate). HasC is an enzyme that catalyzes 
the conversion of UTP-Glc-1-phosphate (glycose-1-P) to 
UDP-Glucose (UDP-Glc), one of the two HA precursors 
(Fig. 3) [66]. HasA adds in strict alternating fashion the 
two HA precursors (UDP-GlcNAc and UDP-GlcUA) to 
the non-reducing end of the growing HA chain, using the 
two UDP-sugar substrates, alternatively creating β1 → 3 
and β1 → 4 glycosydic bonds (Fig. 1) [2].
In addition to HA synthesis, many of these intermedi-
ate molecules are used by the cells as wall components 
(production of peptidoglycan) and teichoic acid compo-
nents [25, 56]. Cloning of the streptococcal HA synthase 
encoding genes in Escherichia coli confirms that only 
HasA enzyme is required for HA biosynthesis when the 
cell is already producing glucuronic acid and N-acetylglu-
cosamine [60].
Over time, a combination of strain improvement and 
cultivation conditions have been performed in order to 
enhance the HA production [67]. The mutant strain from 
S. equi ATCC 6580 was generated using sequential culti-
vations with N-methyl-N′-nitro-N-nitroso-guanidine and 
reached 6–7  g/L of HA in a 100  L fermentor (Table  2). 
In another study [63] a strain of S. zooepidemicus had 
the metabolic pathway of synthesis of HA engineered 
completely by an adjustment of the concentrations of 
the metabolites through the overexpression of the five 
HAS genes encoding for HA. The concentrations of the 
two precursors of HA within the cell affects the molec-
ular weight of the final chains, when the genes involved 
in UDP-N-acetylglucosamine pathway are overex-
pressed the final HA MW increases (~3.4  MDa; double 
the amount found in wild-type strain), and when the 
genes involved in UDP-glucuronic pathway are overex-
pressed the final MW decreases (Table 2). On the other 
hand, overexpression of the enzyme that synthetizes HA 
(HasA) produces an increase in the HA yield [68].
The application of chemical mutagenesis followed by a 
serial selection program has been successfully exploited 
to obtain a hyaluronidase-negative, non-hemolytic, kan-
amycin-resistant, and highly viscous mutants strains of 
S. equi strains [67]. HA production by the S. equi ATCC 
6580 mutant (renamed S. equi ATCC KFCC 10830) was 
tested with and without the addition of lysozyme. When 
lysozyme is added to the cells, the cell wall structure is 
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disintegrated causing a stress to the culture broth during 
the growth, in these cases the HA production expanded 
of 3.65–4.63 g/L. This suggests that the HA is a cell pro-
tective agent produced by the microorganism in response 
to a unfavorable or critic environment [67] (Table 2).
S. zooepidemicus showed potential of HA production 
levels close to those obtained by means of processes that 
use high-value compounds used in the laboratory, while 
using marine industrial by-products as source of carbon 
and aminoacids [69]. The amount of dissolved oxygen in 
the culture medium also affects the production of HA, S. 
zooepidemicus ATCC 39920 was exposed to ultraviolet 
(UV) light and N-methyl-N′-nitro-N-nitrosoguanidinea 
resulting in the mutant strain called G1 [70]. Under 
anaerobic conditions, cell growth and HA synthesis were 
suppressed and the HA MW was only 1.22 MDa with a 
final production of 0.73 g/L. On the other hand, the pro-
duction of HA in an aerobic fermentation was obtained 
with a doubled MW, but there were no changes in bio-
mass or HA yield (Table 2).
Microorganisms genetically modified for HA production
Metabolic engineering has been providing opportunities to 
obtain HA from non-pathogenic, safe microorganisms and, 
hence, an endotoxin-free product since the natural produc-
ing organisms are mostly pathogenic. With these criteria, 
HA has already been produced by a wide range of heter-
ologous hosts, including: Lactococcus lactis [71–75], Ente-
rococcus faecalis [64], Corynebacterium glutamicum [76], 
Agrobacterium sp [58], Escherichia coli [43, 48, 64, 77–79], 
Streptomyces albulus [80], Bacillus subtilis [74, 81, 82], Sac-
charomyces cerevisiae [83], Pichia pastoris [45] and plant 
cell cultures [84, 85]. Many studies have included the evalu-
ation of HA production using different genetic modifica-
tions, HAS proteins, and different hosts as discussed below.
Prokaryotic organism
Among the different domains, bacteria is the main 
exploited for heterologous production of HA. The follow-
ing topics discuss some of the organisms studied so far.
Bacteria
Lactococcus lactis Gram-positive lactic acid bacterium, 
L. lactis is used worldwide as starter for the production 
of numerous products [86]. L. lactis has many desirable 
characteristics for a fermentative microorganism and a 
GRAS status, therefore many attempts has been made to 
genetically modify it for HA production [72].
Table 2 Organisms that naturally produce HA
NR not reported
a Calculated from the values reported by the authors of the maximum production of HA (P) and the consumed substrate (S), defined as Yield = P/S
b Calculated from the values reported by the authors of the maximum production of HA (P) and the cultivation time to obtain this production (t), defined as 
productivity = P/t











Streptococcus zooepidemicus Glucose: 10 0.95 0.09 0.0396 NR [63]
Streptococcus zooepidemicus WSH-24 Glucose: 15 6.6 0.071 0.33 NR [99]
Streptococcus zooepidemicus ATCC 39920 Glucose: 10 2.45 0.12 0.223 NR [3]
Streptococcus equi subsp. zooepidemicus (S. 
zooepidemicus ATCC 35246)
Glucose: 20 NR 0.088 NR 2.4 [100]
Streptococcus equi ATCC 6580 (mutant) Glucose: 80 5.5 NR 0.344 3.8 [57]
Streptococcus equi ATCC 6580 (mutant) Glucose: 80 6–7 0.088a 0.47b 3.2 [57]
Streptococcus zooepidemicus G2 (mutant) Glucose: 40 3.51 NR 0.251 2.19 [60]
Streptococcus zooepidemicus (overexpres-
sion of genes involved in biosynthesis of 
UDP-N-acetylglucosamine)
Glucose: 20 NR 0.075 NR ~3.4 [3]
Streptococcus sp. ID9102 Glucose: 40 6.94 NR 0.289 5.9 [101]
Chlorella cells infected with Chlorovirus NR 0.5–1 NR NR NR [27]
Chlorovirus infected with PBCV-1 NR 6.3 × 10−6 NR 1.6 × 10−6 NR [41]
Chlorovirus with PBCV-1 CV01 NR 7.6 × 10−6 NR 0.95 × 10−6 NR
Chlorovirus with PBCV-1 CVTS1 NR 9.2 × 10−6 NR 1.15 × 10−6 NR
Chlorovirus infected with PBCV-1 (aphidi-
colin)
NR ~1.0 × 10−5 NR 5.3 × 10−6 NR
Chlorovirus with PBCV-1 CV01 (Aphidicolin) NR 14 × 10−5 NR 3.5 × 10−6 NR
Streptococcus sp. ID9102 (KCTC 11935BP) NR 6.94 NR 0.289 5.9 [101]
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Nevertheless, L. lactis does not produce the enzyme 
HA synthase, which has a crucial role in HA produc-
tion. Therefore, initial studies on HA production using 
L. lactis utilized non-integrative plasmids such as pRKN; 
pNZ8148; and their derivatives, for the expression of 
genes encoding HAS proteins [71–73, 75]. It is notewor-
thy that the L. lactis NZ9000 strain transformed with 
pSJR5, co-expressing five different genes (hasA, hasB, 
hasC, hasD and hasE) has exhibited structural and segre-
gational instability, resulting in incorrect gene expression 
or loss of plasmid after few generations [71]. Strains suc-
cessfully transformed with plasmids packed with genes 
hasA-B, hasA-B-C, and hasA-B-D, were respectively 
named strains SJR2, SJR3, and SJR6. Static flask experi-
ments using glucose as a substrate indicated that the 
strain co-expressing the genes hasA and hasB obtained 
a production of 0.097  g/L HA, while the other experi-
ment with the strain co-expressing hasA, hasB and hasC 
genes yielded a maximum production of 0.234 g/L HA, as 
indicated in Table 3, suggesting that the introduction of 
the hasC gene is essential for high HA production [71]. 
In submerged anaerobic fermentations, HA production 
was three times higher (0.72  g/L) using the SJR3 strain, 
in comparison to the SJR2 strain (0.26  g/L). Addition-
ally, when the bioreactor containing a SJR3 culture was 
aerated at 1  vvm, HA production increased to 1.8  g/L. 
Another construct, named SJR6, was assessed for HA 
production and transcription of HA pathway genes, as 
shown in Table 3 [73].
The low levels of HA production conducted with the 
SJR2 strain was hypothesized to be due to low UDP-glu-
cose pyrophosphorylase (hasC) levels [71]. On the other 
hand, the co-expression of the genes hasC, hasA and 
hasB genes (SJR3 strain), increases HA production from 
0.097 to 0.234 g/L. It has been discussed that increased 
HA production levels are due to the increase in UDP-glu-
cose pyrophosphorylase levels in the SJR3 strain culture, 
diverting the flux of glucose-1-phosphate toward UDP-
glucose synthesis. Therefore, different concentrations 
of substrate were tested for each recombinant strain, all 
listed in Table  3. From these results, it is assumed that 
HA biosynthesis depends not only on culture conditions 
and on the combination of heterologous genes incorpo-
rated in the strain but also on the expression level and 
transcriptional regulation of the homologous genes in the 
host genome.
The plasmids pEIrkA, pEIrkB, and pEIrkAB containing 
hasA, hasB, and hasA together with hasB, respectively, 
all from S. equi subsp. Zooepidemicus, have been intro-
duced into L. lactis [72]. The expression of each gene 
was studied in order to relate it to HA production lev-
els. The strain containing only hasA produced 0.08 g/L, 
while the strain containing hasA together with hasB had 
approximately an eight-fold increase in HA production, 
as shown in Table 3. The strain containing only hasB did 
not produce any HA [72].
Recombinant L. lactis strains were developed, resulting 
in two strains called VRJ2AB, carrying HasA and HasB 
genes, and VRJ3ABC, carrying HasA, HasB and HasC 
genes, integrated into their genomes [87]. HA production 
and MWs were, respectively, between 0.14 and 0.68 g/L 
and 4.3 and 3.49 MDa (Table  3). Overall, genome-inte-
grated strains produced a two-fold increase in the HA 
polymer MW when compared to the plasmid-based 
strains. The significant difference in MW of HA derived 
from these strains could be explained by the precur-
sors ratio effects (UDP-GlcNAc/UDP-GlcUA) and the 
HasA/HasB mRNA ratio. In the plasmid-bearing strains, 
HasA gene expression was high, but due to lower HasB 
expression, a sufficient substrate was not available dur-
ing synthesis of HA chains by HA synthases, resulting 
in a relatively lower MW. In genome-integrated strains, 
there were relatively fewer HA synthases available and 
a greater availability of precursors for binding to HA 
synthase, facilitating greater MWs to be synthesized. In 
another study, it was hypothesized that the MW of HA 
can be regulated by hasA/hasB mRNA production levels. 
When the hasA/hasB-mRNA ratio was above 1.00, the 
HA polymer usually had a smaller size when compared to 
ratios below 1.00, whereby hasB mRNA levels are greater 
than hasA [75].
Enterococcus faecalis This bacterium is a Gram-positive 
cocci with a natural habitat in the oral cavity and human 
intestinal lumen [88]. In the literature, there are only a 
few studies involving E. faecalis and the production of 
HA [89]. This might be due to the low total production 
yield obtained when compared to other microorganisms 
as shown in Tables 2 and 3. De Angelis et al. reported that 
the introduction of locus encoding of at least two strepto-
coccal proteins could produce HA in acapsular E. faecalis 
mutants [89]. When HasA was introduced in E. faecalis, it 
was able to synthesize 0.69 g/L HA using 20 g/L of glucose 
(Table 3).
Corynebacterium glutamicum These Gram-positive 
bacteria are the important microorganism with GRAS 
status for industrial amino acid production [90]. Never-
theless, C. glutamicum is also used for the biosynthesis of 
pantothenic acid [91], carotenoids [92], organic acids [93] 
and biofuels [94–96].
Therefore, for HA heterologous production, C. glu-
tamicum was tested as an alternative host [76]. For that, 
a set of expression vectors was constructed contain-
ing HasA, encoding HA synthase from S. equi subsp. 
Zooepidemicus. To analyze the influence of precursors 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 13 of 19de Oliveira et al. Microb Cell Fact  (2016) 15:119 
concentrations in the metabolic pathway, some vec-
tors were constructed containing the genes HasB, HasC, 
and glmU (from Pseudomonas putida KT2440 strain) 
or hemoglobin from bacteria (vgb from Vitreoscilla sp.) 
[97]. The strains which co-expressed HasB, HasC or 
glmU had no result on HA yield and did not improve the 
MW of the product (Table 3). In contrast, co-expression 
of vgb decreased HA yield approximately 1.5-fold and did 
not affect the MW of the product. This study also ana-
lyzed how the media composition affect the HA produc-
tion and MW, and observed that when using the medium 
CGXII, a production of 1.2  g/L was achieved, while the 
MEK700 medium production was almost 3.5 times less. 
On the other hand, the MW obtained in the MEK700 
medium was greater (1.4 MDa) than was obtained in the 
CGXII medium (<0.27 MDa) (Table 3).
Agrobacterium sp. The Agrobacterium ATCC31749 
strain is known as a curdlan polysaccharide producer. The 
efficient production of this glucose polymer implicates an 
effective mechanism for sugar nucleotide UDP-glucose 
synthesis, demonstrating a natural tendency for synthe-
sizing the sugar nucleotide precursor, UDP-glucose [98].
However, HA production studies using Agrobacte-
rium as the host are limited. A single study explored 
three Agrobacterium strains as the host for HA synthe-
sis through the expression of the pmHas gene from P. 
multocida: Agrobacterium sp. ATCC31749, an overpro-
ducing curdlan strain and Agrobacterium sp. LTU261 
and LTU265, with defects in curdlan synthesis regula-
tion and transport, respectively [58]. The recombinant 
strains had the ability to synthesize HA with production 
levels resulting in 3.0, 2.3 and 2.4  g/L, respectively, and 
with a MW around 1.56, 2.17 and 0.72 MDa, respectively, 
as indicated in Table  3. The HA MW produced from 
Agrobacterium sp. LTU261 was approximately 1.3 times 
greater than commercial HA extracted from Streptococ-
cus (Table 3).
Escherichia coli The first use of recombinant E. coli for 
HA production was to validate the function of the encod-
ing gene for the HAS from S. pyogenes Group A [64]. In 
the early 2000s, the use of a recombinant E. coli showed 
the possibility of producing human HAS [40]. Therefore 
the first human HAS successfully expressed in E. coli was 
the catalytic region of human HAS2 isoform. Neverthe-
less, the levels of HA produced were not reported in this 
study [40]. In 2007, CPS1 cDNA from C. neoformans was 
expressed in E. coli OP50 and resulted in a strain that was 
able to synthesize HA with a productivity of 4 ng/hr/µg 
total protein (Table 3) [50].
In recent years, more efficient production in E. 
coli has been achieved through codon optimization, 
overexpression of HasB and random mutagenesis, as 
shown in Table  3 [79, 99]. Different fermentation pro-
files have shown that HA MW and concentration were 
increased from 0.38 to 1.9 MDa and from 0.148 to 
0.202 g/L, respectively [79] (Table 3).
In a follow up study, a strain of E. coli was success-
fully engineered to produce HA through the expression 
of pmHas gene from P. multocida subsp. multocida [59]. 
The strain produced about 0.5 g/L HA cultured in shake 
flask and about 2.0–3.8  g/L in a fed-batch fermentation 
process in a 1-L fermentor. In the same year, HA produc-
tion was increased in an E. coli strain, JM109, modified to 
co-produce two enzymes, P. multocida HA synthase and 
E. coli K5 UDP-glucose dehydrogenase.
Streptomyces albulus This soil-dwelling actinomycete is 
known for producing a wide range of bioactive second-
ary metabolites [100]. It has been proposed that enhanc-
ing the amount of intracellular ATP is a good strategy to 
achieve higher MW HA and improve the productivity in 
microorganisms [80]. Considering this, S. zooepidemicus 
hasA gene was modified and expressed in the S. albulus 
pJHA4 strain, which has the potential to generate ATP at 
high levels, under the regulator of a late-log growth phase-
operating promoter. This resulted in efficient production 
of HA in the 2.0 MDa MW range, which is greater than 
typical bacterial HA (which ranges from 0.5 to 2.0 MDa), 
indicating that the increased amount of intracellular HA 
precursors, through higher levels of ATP available to 
the cell, can lead to increased HA production, achieving 
6.2 g/L after 72 h fermentation.
Bacillus subtilis This bacterium is a Gram-positive, 
spore-forming microorganism found in soil, water and in 
association with plants. It is one of the most broadly used 
models for genetic engineering. This bacteria has been 
utilized for the production of pharmaceuticals due to its 
well-characterized production of secondary metabolites 
that can be used as antimicrobial agents [101] and sur-
factants [102], besides being an important enzyme pro-
ducer. The use of a B. subtilis strain is an excellent strat-
egy for HA production since B. subtilis has GRAS status, 
ensuring that endotoxin-free products can be developed 
in industrial-scale.
A recombinant B. subtilis strain was developed, 
expressing S. equisimilis HA synthase gene, hasA, result-
ing in the production of HA with MW values around 1 
MDa (Table 3). The association of hasA gene with other 
genes related to the biosynthesis of UDP-precursors has 
been tested, resulting in different operons, transformed 
in recombinant B. subtilis strains. It was observed that 
UDP-glucuronic acid level is a limiting factor for the 
HA production, in B. subtilis. The strategy used for the 
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development of the recombinant strains was based on 
the identification of hasB homologous genes in B. sub-
tilis (hasB and tuaD) and then overexpressed aiming at 
increased production level of intermediates for HA bio-
synthesis. After that, hasA was cloned under the control 
of a strong S. equisimilis promoter, called amyQ. The 
product obtained in the B. subtilis system was confirmed 
to be secreted and of similar quality, compared to com-
mercial products [81].
In another study, a plasmid containing a hasA gene 
and the hasB gene from Streptococcus or tuaD (the same 
activity of hasB from Streptococcus) in B. subtilis were 
integrated into the amyE locus of the B. subtilis chromo-
some [74]. Within this construction, all genes were under 
the control of a strong constitutive promoter named 
VegII from B. subtilis. They coexpressed Vitreoscilla 
hemoglobin (VHb) in a B. subtilis concomitant to the 
HA-encoding genes which resulted in a 25  % increased 
growth rate as well as double the HA production. The 
strain expressing VHb, hasA and tuaD under the same 
regulation obtained HA in a concentration of 1.8  g/L 
after 30 h of cultivation (Table 3). It has also been shown 
that cells of B. subtilis containing the expression cassette 
with the tuaD gene (1.14 g/L) are 30 % more efficient in 
producing HA than cells containing only the hasB gene 
(0.84 g/L) [74].
More recently, a two-stage induction strategy has been 
utilized in the B. subtilis 168 (BGSC strain) aimed at 
increasing HA yield [82]. In this study, two constructions 
were used: (1) plasmid pAX01, which was used for clon-
ing the HA synthase gene from P. multocida (PmHAS); 
(2) plasmid pHCMC05, which was used for the construc-
tion of recombinant operons for the enzymes related to 
the synthesis of the UDP-precursor sugars. The TPG223 
strain was obtained after transformation with both vec-
tors, pAX01-PmHAS and pHCMC05-tuaD-gtaB (tuaD 
and gtaB coding for UDP-GlcUA biosynthesis), this 
strain achieved HA production of 6.8  g/L and MW of 
4.5 MDa (Table 3). Another strategy was designed to test 
for the UDP-GlcNAc, adding the gcaD gene to the sys-
tem, gcaD coding for products related to UDP-GlcNAc 
biosynthesis. This strain, PG6181, obtained HA produc-
tion of 2.4  g/L and MW of 0.013  MDa (Table  3). The 
results observed in those studies point to the relevance 
of UDP-GlcUA levels to the overproduction of HA in B. 
subtilis expression system.
Eukaryotic organisms
Numerous bacterial systems for the heterologous produc-
tion of HA have been presented. Nevertheless, in the last 
few years, the use of eukaryotic organisms has increased. 
Here we introduce some eukaryotic systems described in 
the literature that are used for the production of HA.
Yeasts Technologies that use yeast for the production of 
HA are more advantageous over other methods that are 
currently available on the market. For instance, there are 
yeast species that are not pathogenic, and its use for HA 
production would decrease downstream costs. Addition-
ally, the extensive genomic knowledge of various yeasts 
together with available genetic tools allows target genetic 
modification for heterologous production of HA. Moreo-
ver, some yeast species already produce the intermediates 
for HA production such as glucuronic acid and N-acetyl-
glucosamine and, in theory, in those species that require 
fewer genetic modifications. Finally, some yeast species 
are already widely used in many industrial processes with 
known cultivation technologies which could also reduce 
costs in large-scale HA production. HA production in 
yeast is not as characterized as in bacteria, however, there 
are some studies which indicate the possibility of using 
yeast for the heterologous production of HA.
Saccharomyces cerevisiae This yeast is widely used in 
industrial processes. Its biology is the most understood of 
all the yeasts due to its utilization for beer, bread and wine 
production. Nevertheless, S. cerevisiae does not produce 
HA naturally. Therefore, it was genetically modified nearly 
20 years ago for the production of HA [83]. For that, the 
hasA gene DG42 from Xenopus was introduced into the 
S. cerevisiae strain using pYES2, an epissomal plasmid. 
The recombinant S. cerevisiae INSc1 strain containing 
the plasmid has been shown to incorporate glucuronic 
acid and N-acetylglucosamine from exogenously supplied 
UDP-sugar nucleotides into a high MW polymer and has 
produced about 1–10 MDa [83].
Pichia pastoris The development of recombinant P. pas-
toris for HA production has been recently described [45]. 
In this study, strains have been modified with the intro-
duction of five genes: HasC, glmU (pyrophosphorilase), 
pgI (phosphoglucoisomerase), HasA and HasB (Fig. 3). In 
this study, two types of plasmid were utilized: the vector 
pAO815 and the vector pGAPZB, which have an induc-
tive promoter (AOX) and a constitutive promoter (GAP), 
respectively. Cassettes containing HasB, HasC, glmU and 
pgi were inserted in different combinations into pGAPZ 
B, whereas cassettes containing HasA, HasB, HasC, 
glmU and pgi were inserted into different combinations 
in pAO815 and both vectors were inserted into P. pasto-
ris. The idea was to use the vector containing constitutive 
promoters to cause an accumulation of both acid precur-
sors in the cell and in a second step activate the inductive 
promoter preceding the HasA gene, leading to increased 
HA production and higher MW HA. The strategy also 
included performing fermentation of P. pastoris at a tem-
perature below the optimal growth temperature to avoid a 
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deviation of the carbon flux from the acid precursors for 
the wall synthesis and consequently increase the produc-
tion yield of HA. This strategy achieved production values 
between 0.8–1.7  g/L of HA with a MW in the range of 
1.2–2.5 MDa.
Plant cell culture
Plant cell systems for the production of industrial materi-
als show advantages over bacterial and mammalian vec-
tors, such as: (1) the lack of human transmissible viruses 
and no risk of spongiform encephalopathies transmis-
sion; (2) costs related to the production are lower when 
compared to conventional fermentation processes; (3) 
as a photosynthetic system which fixates carbon dioxide, 
can be considered eco-friendly, reducing global warming 
gases levels [85].
Hyaluronidase is an enzyme that depolymerizes HA 
and thus increases membrane permeability, decreases 
viscosity, and makes tissues more readily permeable 
[103]. It can be used as a “spreading factor”, enabling the 
diffusion of molecules through the tissues [104]. Four 
genes coding for hyaluronidases in humans, rHuHyal-1, 
-2, -3 and -4, have been successfully expressed and puri-
fied using Nicotiana benthamiana as host [84]. Experi-
ments performed with those enzymes demonstrated that 
post-translational protein modifications patterns, bio-
chemical properties and activities were similar to those 
shown by animal isolated hyaluronidases.
After the transformation of tobacco-cultured cells 
(BY-2) with a chloroviral HA synthase (cvHAS) gene to 
produce HA, HA was detected, but not measured by the 
authors [85].
Patent publications
In accordance with a database containing over 80 mil-
lion patent documents from about 90 different countries, 
the number of patent documents containing “hyaluronic 
acid” in the title is growing every year, as shown in the 
Fig. 5a. There is a total of 4844 patents containing “hya-
luronic acid” (or synonymous words) in the publication 
title. Most of these publications are related to the devel-
opment of medical applications and formulations, fol-
lowed by food and chemical industries (Fig. 5b). Among 
the techniques used in medical formulations, more than 
half are associated with the production of cosmetic 
preparations (62 %), followed by preparations for use in 
surgeries in various areas (28 %), such as ophthalmology. 
Still, in relation to patent registry for the production of 
HA, there is a severe disadvantage in price and purifica-
tion of HA extraction via animal origin, thus, many meth-
ods using plants and microorganisms for the production 
of HA have emerged. According to a search in the same 
patent databases listed above, there are different projects 
using host cells for the production of HA, as illustrated in 
Table 4.
Conclusions and perspectives
HA has innumerous biological uses in the human body, 
from signaling processes during embryonic development 
to wound healing. Furthermore, it is important for the 
treatment of arthritis and osteoarthritis. Additionally, it 
has high commercial value compared to extracellular pol-
ysaccharides obtained from other microorganisms.
Previously, HA used to be extracted from animal waste. 
Nowadays, it is being replaced by production through 
Fig. 5 Patents: a Number of patent publications involving hyaluronic acid since 1975, in the world. b Key areas covered by the hyaluronic acid 
patent market. In blue are the patents involving preparations for medical purposes, in red are the patents involving processes for techniques used in 
Biochemistry, in green are the patents involving foods and foodstuffs, in orange are the patents involving processes for the development of hyalu-
ronic acid chains and in yellow are others Source: Espacenet Patent Database. Accessed on 02/11/2015
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bacterial fermentation. However, the fact that the micro-
organisms that naturally produce HA are pathogenic 
has stimulated studies to obtain this biopolymer using 
non-pathogenic and industrially friendly microorgan-
isms. Nevertheless, up to now there has been no heter-
ologous host producing as much HA as the natural ones. 
However, this fact has not discouraged researchers from 
attempting to obtain an ideal host for the production of 
heterologous HA. Rather, the search for this organism 
has included a wide variety of organisms such as bacteria, 
yeast, plants and virus-infected algae.
Besides the importance of heterologous produc-
tion of hyaluronic acid by GRAS microorganisms, the 
research involving this polymer should advance to over-
come the challenges regarding the metabolic route of its 
production. For example: (1) the competition between 
hyaluronic acid synthesis and cell growth (cell wall bio-
synthesis) observed in all the producers; (2) the inversely 
proportional relationship between the high concentra-
tion production and high MW; (3) the limitation of the 
fermentation in the bioreactor when it reaches 10  g/L 
due to the high viscosity of the medium; (4) the control of 
the amount of has gene transcribed, that directly affects 
the production of hyaluronic acid and the health of the 
cell wall (which can make unviable cells); (5) the control 
and equilibrium of the amount of the both precursors 
necessary for hyaluronic acid synthesis, where it is pre-
viously described that low concentrations of N-acetyl-
glucosamine causes an inhibition of the synthesis, (6) the 
co-production of molecules like lactic acid that inhib-
its cell growth due to lower pH, and, lastly, (7) the bal-
ance between the recycling of cofactors (ATP, UTP and 
NADH) available in the cell for the use in the biosynthetic 
processes. All these challenges require specific studies to 
increase the knowledge for the HA optimal production 
conditions.
Furthermore, the advances in genetic engineer-
ing tool, especially in the genome editing area should 
contribute for the development of novel strains over 
producing HA. Recently, CRISPR/Cas9 technology is 
attracting more space withint the scientific community 
[105]. After the first use, CRISP-CAS9 has been used in 
a wide range of microorganisms, including the bacteria 
Escherichia coli [106] and yeast Saccharomyces cerevi-
siae [107].
However, in literature, there are no reports of any use 
of CRISPR/Cas9 technology involving heterologous pro-
duction of hyaluronic acid, perhaps by the very recent 
nature of the technology. All hyaluronic acid stud-
ies involve traditional technologies, such electropora-
tion techiques, homologous recombination in yeast [45] 
and gene insertion via plasmid [81]. The possible use of 
CRISPR/Cas9 in the production of hyaluronic acid could 
generate some advantages, including: (1) gene insertion 
in specific regions, such close of strong promoters, (2) 
considerable increase efficiency of clones with has gene, 
(3) regulation of genic transcription through the inclu-
sion of transcription factors and (4) repression of genes 
that act directly or indirectly by inhibiting the synthesis 
of hyaluronic acid.
Among the microorganisms studied in this review, the 
yeast P. pastoris has been a host with commercial poten-
tial to produce HA. This is due to the combination of its 
production reaching an output of 0.8–1.7 g/L with a MW 
from 1.2 to 2.5 MDa [45]. Therefore, further studies on 
heterologous production using P. pastoris as a host may 
allow for greater production yields.
It is worth emphasizing that the ideal molecular size 
of HA will depend on its application. For example, in 
order to promote the healing of skin wounds and venous 
leg ulcers and to manage chronic wounds, a high MW 
is needed, while in rheumatoid and osteoarthritis, the 
MW and concentration of synovial fluid-HA are reduced. 
Additionally, the production mode can interfere directly 
in the production yield. Therefore, considering a cultur-
ing process using two stages (growth and production) 
could increase HA production, because there is a compe-
tition of HA precursors, which are also required for cell 
wall synthesis, for example.
It is noteworthy that the elucidation of biosynthetic 
pathways for HA-producing microorganisms and the 
use of genetic engineering combined with the opti-
mization of biotechnological processes certainly cor-
roborate with the increase of such outcomes in the 
heterologous production of HA. Therefore, the future 
Table 4 Engineered organisms patented for  hyaluronic 
acid synthesis
a Yeast specie not informed
Host cell Patent number Patent date
Escherichia coli US2014099673 (A1) 10/04/2014
EP2614088 (A1) 17/07/2013
CN102154190 (A) 17/08/2011
Bacillus subtilis EP2614088 (A1) 17/07/2013
Bacillus megaterium US2014099673 (A1) 10/04/2014
Streptococcus zooepidemicus CN103993031 (A) 20/08/2014
Streptococcus thermophilus JP2012130287 (A) 12/07/2012
Pichia pastoris CN104212732 (A) 17/12/2014
Yeast cella JP2007174957 (A) 12/07/2007
Alga cell EP2914716 (A1) 09/09/2015
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of HA production process will certainly be the asso-
ciation of metabolic engineering and process design 
strategies.
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